This study focuses on treating alcoholic hepatitis, a severe liver condition caused by excessive alcohol consumption. The research evaluates different treatment approaches using two medications: prednisolone, a corticosteroid medication that helps reduce inflammation in the liver, and N-acetylcysteine, a substance that may help protect liver cells from damage.

The study compares three different treatment approaches: standard treatment with prednisolone for 30 days, extended prednisolone treatment for 60 days, or a combination of standard prednisolone treatment with N-acetylcysteine given over 5 days. The purpose is to determine which treatment method is most effective in helping patients recover from severe alcoholic hepatitis and maintain stable liver function after 90 days.

During the study, participants will receive either prednisolone tablets taken by mouth, N-acetylcysteine given through an intravenous line (directly into a vein), or placebo, depending on their assigned treatment group. Some patients will receive additional supportive treatments including dextrose and saline solutions. The study will monitor patients’ liver function and overall health throughout the treatment period and follow-up visits.